Vykhristenko L.R.
Clinical estimation of efficacy and safety of low-dose oral allergovaccines in allergic rhinitis
Abstract. The purpose of this research was to study the efficacy and safety of new low-dose oral allergovaccines AV-1P and AV-2P (producer - «Dialek», the Republic of Belarus) for the treatment of patients with allergic rhinitis (AR). The study involved 34 patients. The first group (12 patients) received low-dose oral allergovaccine AV-1P, 10 patients were given low-dose oral allergovaccine AV-2P (the 2nd group), 12 patients received standard drug treatment for AR (the 3rd group). In the 1st and the 2nd groups we achieved the reduction in symptoms of AR by 50% (p=0,005) and 54,3% (p=0,008), the need for antihistamine drugs by 50% (p=0,04) and 63% (p=0,04), for intranasal glucocorticosteroids during treatment with allergovaccine AV-1P - by 83,3% (p=0,04). Allergovaccines reduced skin sensitization, modulated the levels of IgE-antibodies, IL-10 and TGF- in the serum of patients. Slight side effects were observed during treatment with oral allergovaccines.
Key words: low-dose oral allergovaccine, allergic rhinitis.
